U.S. markets close in 40 minutes
  • S&P 500

    4,419.23
    +7.44 (+0.17%)
     
  • Dow 30

    35,126.62
    +65.07 (+0.19%)
     
  • Nasdaq

    14,835.07
    -1.93 (-0.01%)
     
  • Russell 2000

    2,212.05
    +2.40 (+0.11%)
     
  • Crude Oil

    72.07
    0.00 (0.00%)
     
  • Gold

    1,797.00
    -4.80 (-0.27%)
     
  • Silver

    25.25
    +0.02 (+0.07%)
     
  • EUR/USD

    1.1808
    +0.0038 (+0.32%)
     
  • 10-Yr Bond

    1.2760
    -0.0100 (-0.78%)
     
  • GBP/USD

    1.3813
    +0.0059 (+0.43%)
     
  • USD/JPY

    110.3810
    -0.1290 (-0.12%)
     
  • BTC-USD

    40,136.55
    +5,788.90 (+16.85%)
     
  • CMC Crypto 200

    952.65
    +37.16 (+4.06%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Cytokinetics says Lou Gehrig's drug fails mid-stage trial

April 25 (Reuters) - Cytokinetics Inc said its experimental treatment for Lou Gehrig's disease - a progressive neurodegenerative disorder - failed the main goal in a mid-stage trial.

The study tested the efficacy of the drug, tirasemtiv - one of the company's lead compounds - against a placebo in 711 patients with amyotrophic lateral sclerosis (ALS).

The San Francisco-based company's stock was halted before the bell on Friday.

(Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel)